RT Journal Article
T1 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
A1 Garcia-Medina, Jose J
A1 Benitez-Del-Castillo, Javier
A1 Rodríguez-Agirretxe, Iñaki
A1 Lopez-Lopez, Fernando
A1 Moreno-Valladares, Antonio
A1 VISIONARY Study Group (Spain), 
K1 fixed-dose combination
K1 ocular hypertension
K1 open-angle glaucoma
K1 preservative-free topical medication
K1 tafluprost
K1 timolol
AB Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study, examining the effectiveness, tolerability, and safety of the preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in the treatment of OAG and OHT. Methods: An observational, multicenter prospective study examined treatment outcomes following a switch to PF tafluprost/timolol FC in adult OAG/OHT patients demonstrating insufficient response to beta-blocker or prostaglandin analog (PGA) monotherapy. Primary end point was mean change in intraocular pressure (IOP) from baseline at month 6. Changes in the severity of ocular signs and symptoms were also assessed. Results: Overall, 92 patients (51.1% female) were included. Mean (standard deviation) age was 68.3 (12.1) years. Mean IOP was reduced from 21.9 mmHg at baseline to 16.7 mmHg at month 6 (22.3% decrease; P 
YR 2022
FD 2022-02-28
LK http://hdl.handle.net/10668/19702
UL http://hdl.handle.net/10668/19702
LA en
DS RISalud
RD Apr 6, 2025